Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 7s Year: 2005
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Physiological impairments and exacerbation risk in COPD patients with less symptom and no frequent exacerbation history. Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Predictors of asthma exacerbation after treatment cessation Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Mild improvement in symptoms and pulmonary function in a long-term follow-up of patients with TDI-induced asthma Source: Eur Respir J 2005; 26: Suppl. 49, 604s Year: 2005
Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients? Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma Source: Eur Respir J, 55 (1) 1900964; 10.1183/13993003.00964-2019 Year: 2020
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Effects of therapy for rhinosinusitis in signs and symptoms of asthma in children Source: Eur Respir J 2007; 30: Suppl. 51, 383s Year: 2007
Early recurrent exacerbation and exacerbation therapy Source: Eur Respir J 2006; 28: Suppl. 50, 841s Year: 2006
Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017
Evaluation of physical sings and symptoms in patients with acute exacerbation of COPD Source: Annual Congress 2008 - Prognosis in COPD Year: 2008
Mechanisms of dyspnoea relief following radiation treatment in a patient with severe COPD Source: Eur Respir J 2011; 38: 728-730 Year: 2011
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007
The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009